SCA
PCRX icon

Secor Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Secor Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-19,119
Closed -$872K – 556
2017
Q1 		$872K Buy
+19,119
New +$826K 0.1% 263

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Secor Capital Advisors's PCRX Position: Q2 2017 in Review

Secor Capital Advisors sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 19,119 shares — an estimated $872K sold.

Secor Capital Advisors first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $872K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Secor Capital Advisors reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 19,119 Pacira BioSciences shares in Q2 2017, an estimated $872K.
  • Secor Capital Advisors first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
  • Secor Capital Advisors's Pacira BioSciences position peaked at $872K in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Secor Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.